HR and breast carcinoma: In monarchE, a randomized phase III trial that investigated the addition of abemaciclib to endocrine therapy in patients with HR+/HER2−, node-positive, high-risk early breast cancer, a compilation of clinicopathological factors including nodal status, tumor size, grade, and Ki-67 were used to define “high risk” [3].